Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
SYNLOGIC, INC. (SYBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
08/16/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/10/2023 8-K Quarterly results
Docs: "Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update - Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU - Cambridge, Mass. August 10, 2023 – Synlogic, Inc. , a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the second quarter ended June 30, 2023, and provided an update on its pipeline programs. “With our pivotal Phase 3 study, Synpheny-3, now underway, we are focused on trial execution and ensuring access, inclusion and an optimal experience for the patients who participate in this landmark ..."
05/11/2023 8-K Quarterly results
Docs: "Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB1934 as a potential treatment for PKU - Cambridge, Mass. May 11, 2023"
03/29/2023 8-K Quarterly results
01/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria"
12/15/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria ; SYNB1934 Advances to Phase 3",
"Slide Presentation"
09/06/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/11/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Presentation"
03/03/2022 8-K Quarterly results
01/24/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "Synlogic Reports Third Quarter Financial Results and Provides Business Update",
"Presentation"
11/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria"
09/23/2021 8-K Quarterly results
09/20/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
07/30/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR CONTACT:"
06/17/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease Cambridge, Mass. June 17, 2021 - Synlogic, Inc. , a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic ™ medicine for the treatment of inflammatory bowel disease . Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic medicine addressing an undisclosed novel target in IBD. “Our mission is to develop Synthetic Biotic medicines that benefit patients in meaningful ways,” said David Hava, Ph.D., Synlogic's Chief Scientific Officer. “We are excited to expand ..."
06/11/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy